Chella Naveen, Tadikonda Ramarao
National Institute of Pharmaceutical Education and Research , Hyderabad, Andhra Pradesh , India .
Drug Dev Ind Pharm. 2015 Jun;41(6):888-97. doi: 10.3109/03639045.2014.911308. Epub 2014 May 5.
Solid dispersion (SD) technique is a promising strategy to improve the solubility and dissolution of BCS class II drugs. However, only few products are marketed till today based on SD technology due to poor flow properties and stability. The present work was intended to solve these problems by using combination approach, melt dispersion and surface adsorption technologies. The main aim of the present work is to improve the absorption in the stomach (at lower pH) where the absorption window exists for the drug by improving the dissolution, resulting in the enhancement of oral bioavailability of poorly soluble, weakly acidic drug with pH dependant solubility, i.e. valsartan. Melt dispersion granules were prepared in different ratios using different carriers (Gelucire 50/13, PEG 8000 and Pluronic F-68) and lactose as an adsorbent. Similarly, physical mixtures were also prepared at corresponding ratios. The prepared dispersion granules and physical mixtures were characterized by FTIR, DSC and in vitro dissolution studies. DSC studies revealed reduction in the crystallinity with a possibility of presence of amorphous character of drug in the dispersion granules. From dissolution studies, valsartan Gelucire dispersion (GSD4; 1:4 ratio) showed complete drug release in 30 min against the plain drug which showed only 11.31% of drug release in 30 min. Pharmacokinetic studies of optimized formulation in male Wistar rats showed 2.65-fold higher bioavailability and 1.47-fold higher Cmax compared to pure drug. The melt dispersion technology has the potential to improve dissolution and the bioavailability of BCS class II drugs.
固体分散体(SD)技术是改善BCS II类药物溶解度和溶出度的一种很有前景的策略。然而,由于流动性差和稳定性问题,到目前为止基于SD技术上市的产品很少。本研究旨在通过采用熔融分散和表面吸附技术相结合的方法来解决这些问题。本研究的主要目的是通过改善溶出度来提高药物在胃中(较低pH值)的吸收,胃中存在药物的吸收窗,从而提高具有pH依赖性溶解度的难溶性弱酸性药物(即缬沙坦)的口服生物利用度。使用不同的载体(Gelucire 50/13、PEG 8000和普朗尼克F-68)和乳糖作为吸附剂,以不同比例制备熔融分散颗粒。同样,也以相应比例制备物理混合物。通过傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)和体外溶出度研究对制备的分散颗粒和物理混合物进行表征。DSC研究表明结晶度降低,分散颗粒中可能存在药物的无定形特征。从溶出度研究来看,缬沙坦Gelucire分散体(GSD4;1:4比例)在30分钟内显示药物完全释放,而普通药物在30分钟内仅释放11.31%。雄性Wistar大鼠体内优化制剂的药代动力学研究表明,与纯药物相比,生物利用度提高了2.65倍,Cmax提高了1.47倍。熔融分散技术有潜力改善BCS II类药物的溶出度和生物利用度。